Abstract: The present application relates to compounds of formula (I?) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Abstract: The present application relates to compounds of formula (I?) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Abstract: The present application relates to compounds of formula (I) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Abstract: Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

Abstract: A humid gas stream is dehumidified by bringing that stream into contact with the front surface of a hydrophilic capillary condenser layer that captures the water and moves it adjacent the rear surface of the capillary layer. A semi-permeable collodion membrane, is disposed on the rear capillary surface of the condenser layer, and an osmotic fluid, such as glycerol, is disposed adjacent the collodion membrane. An osmotic driving force, resulting from a water concentration gradient across the collodion membrane, transports the condensed water from the condensing layer through the thickness of the membrane and into an osmotic fluid. The collodion membrane also inhibits the osmotic fluid from flowing into the condenser layer.

Abstract: A humid gas stream is dehumidified by bringing that stream into contact with the front surface of a hydrophilic capillary condenser layer that captures the water and moves it adjacent the rear surface of the capillary layer. A semi-permeable collodion membrane, is disposed on the rear capillary surface of the condenser layer, and an osmotic fluid, such as glycerol, is disposed adjacent the collodion membrane. An osmotic driving force, resulting from a water concentration gradient across the collodion membrane, transports the condensed water from the condensing layer through the thickness of the membrane and into an osmotic fluid. The collodion membrane also inhibits the osmotic fluid from flowing into the condenser layer.